Dr Reddy’s Lab launches generic eye treatment medication in US
PTI, Jan 27, 2023, 5:13 PM IST
Representative Image (Source: Pexels)
New Delhi: Dr Reddy’s Laboratories on Friday said it has launched Difluprednate Ophthalmic Emulsion, used in the treatment of pain and swelling in the eyes caused by infection or allergy after eye surgery, in the American market.
The company has launched the medication, a generic version of Durezol (Difluprednate Ophthalmic Emulsion 0.05 per cent) in the US market, after getting approval from the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a statement.
As per IQVIA data, the Durezol brand and generics had sales of around USD 40 million in the US for the most recent twelve months ending in November 2022. Dr Reddy’s shares on Friday ended 2.78 percent up at Rs 4,321.35 apiece on the BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
RBI: After another status quo year, all eyes on a growth-propping rate cut with new Guv at helm
Front-running case: Sebi bans 9 entities from market , impounds illegal gains of over Rs 21 crore
Global trends, FIIs’ move to dictate trends in markets in holiday-shortened week: Analysts
GST Council postpones decision to cut tax on insurance, rate panel defers report submission
GST Council meet to decide on lower taxes on insurance policies, ATF inclusion
MUST WATCH
Latest Additions
Kannada Sahitya Sammelana: Food distribution creates stir
Rohit gets hit in nets, practice pitches on slower side
India & Kuwait elevate ties to strategic level; ink defence pact after PM Modi meets top Kuwaiti leaders
In Kuwait, PM Modi meets yoga practitioner, other influencers from Gulf country
Notorious gangster wanted in UAPA case arrested at Nepal border
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.